HRI takes home top award at annual scientific meeting

Awards and Achievements
Dr Siân Cartland from HRI's Vascular Complications Group has been awarded the AVBS Young Investigator/Early Career Researcher (YI/ECR) Best Oral Presentation at the Joint Annual Scientific Meeting in Hobart. 

The Annual Scientific Meeting of the Australian Vascular Biology Society (AVBS) was held as a joint meeting with the Australian Atherosclerosis Society (AAS) and High Blood Pressure Research Council of Australia (HBPRCA) from 7-10 December.

Sixteen HRI researchers were selected for oral and poster presentations based on abstracts submitted to the AVBS, AAS and HBPRCA.

Convened by Dr Mary Kavurma from HRI's Vascular Complications Group, the meeting brought together researchers from across the country to share ideas.

Congratulations to all HRI Researchers who were invited to speak and selected to present:

AVBS Invited Speakers

Dr Christina Bursill, Immunobiology Group Leader

Vegfr2 is activated by high-density lipoproteins (HDL) and plays a key role in the proangiogenic effects of HDL in ischaemia

Dr Anna Waterhouse, Cardiovascular Materials Group Leader

Material surface modification and medical device thrombosis

YI/ECR Oral Finalists

Dr Siân Cartland, Vascular Complications Group WINNER

Non-alcoholic fatty liver disease, vascular inflammation and insulin resistance are exacerbated by TRAIL deletion in mice

Dr Roxane Darbousset, Thrombosis Group

14-3-3 regulates the mitochondrial respiratory reserve linked to platelet phosphatidylserine exposure and procoagulant function

Dr Carmine Gentile, Free Radical Group

Cardiac spheroids as novel 3d in vitro models to study human heart biology and pharmacology

Student Oral Finalists

Ms Dhanya Ravindran, Immunobiology Group

The rate of atherosclerosis development determines changes in plaque volume and composiion following gene transfer of the borad spectrum chemokine binding protein 'M3'

Mr Pradeep Manuneedhi Cholan, Vascular Complications Group

Vascular TRAIL expression is increased in endothelial cells by angioensin II.

YI/ECR Moderated Poster Finalists

Ms Sophie Maiocchi,Thrombosis Group

A novel visualisation technique to investigate thrombo-inflammation during intestinal ischemia reperfusion

Oral Presentations

Dr Bronwyn Brown, Inflammation Group

Low-density lipoproteins modified by myeloperoxidase-macrophage phenotype and function

Dr Mike Wu, Thrombosis Group

Identification of a novel neutrophil-dependent thrombotic mechanism in the lung

Dr Anisyah Ridiandries, Immunobiology Group

Broad spectrum CC-chemokine inhibition improves wound healing and wound angiogenesis

Dr Joanne Tan, Immunobiology Group

microRNA-181C and its putative target TRIM2 mediate the ability of high density lipoproteins to rescue diabetes-impaired angiogenesis

Poster Presentations

Ms Seren Ucak, High Blood Pressure Group

Power specctrum analysis as a measure of vascular rectivity: exploring neural control of cardiovascular function

Mr Pradeep Manuneedhi Cholan, Vascular Complications Group

TRAIL suppresses superoxide producation in diseases vessels and enhances antioxidant expression in endotherial cells

Dr Siân Cartland, Vascular Complications Group

TRAIL modulates monocyte/macrophage phenotype to exacerbate atherosclerosis

Mr Scott Genner, Vascular Complications Group

TRAIL protects against fatty liver in vivo and in vitro

Investigating the role of TRAIL in promoting an angiogenic response

Mr Imala Alwis, Thrombosis Group

Investigating the biochemical and biophysical mechanisms that influence excessive leukocyte recruitment on platelet thrombi following ischemia–reperfusion injury

Dr Monica (Yuen Ting) Lam, Translational Research and Bioengineering Group

Genomic action of androge receptor modulates androgen augmentation of ischaemia-induced neovascularisaion

Previous
Next

Related news

Crystal ball molecule predicts diabetes before it strikes

HRI researchers have developed a simple test to predict diabetes more than a decade before it strikes, a breakthrough that could help ease the impending diabetes epidemic. The team has uncovered an important molecule found in liver fat that can identify who is most at risk of developing diabetes and other cardio-metabolic disorders like liver disease.  

Read more

New drug hope to target silent killer

An exciting new treatment for very high blood pressure is on the horizon after a world-first discovery by Heart Research Institute scientists, who have uncovered a brain chemical instrumental in triggering hypertension, the so-called silent killer responsible for the deaths of thousands of Australians each year.

The researchers are optimistic the results, published this week in the American Journal of Physiology-Heart and Circulatory Physiology, will ultimately lead to a powerful new treatment that blocks a neurotransmitter and frees patients from the dangers of hypertension. 

Read more

Gout drug mends broken hearts

A drug used to treat arthritis has been found to clear clogged arteries in heart attack survivors, world-first Australian research shows.

The landmark discovery by Associate Professor Sanjay Patel, Leader of the Cell Therapeutics Group, and his team at the HRI paves the way for a cheap, simple and effective treatment regime that could protect thousands of Australian heart patients from future attacks that might kill them or further damage their heart. 

Read more